Amarin Corporation plc

AI-generated fair value estimate for this company.

Method: 10-year revenue-and-margin-ramp unlevered FCF DCF: $186.23M TTM revenue (down 15.1% YoY from generic competition for VASCEPA) declining -10%/-8%/-6%/-4%/-2% in years 1-5 then flat in years 6-10 as international expansion offsets US erosion; FCF margin ramping from 5% to 10% as announced ~$70M cost cuts take effect; 11% discount rate; 1% terminal growth; $302.23M net cash added ($307.82M cash less $5.59M debt); 21.12M shares outstanding.

Reasoning: Amarin's VASCEPA franchise faces genuine generic erosion, but the company holds net cash exceeding its entire current market capitalization, so a DCF combining a conservative declining-then-stabilizing operating value with the verifiable net cash balance is the most accurate way to capture intrinsic value that the depressed market price may be understating.